Form 4 for STLN Starling Oncology, Inc.
Accepted 2024-12-05 00:00:00 ET · period of report 2024-12-03 · accession 0001799191-24-000065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-05 | 2024-12-03 | STLN | Castle Jeremy | COO | D - Sale to Iss | $0.16 | -1,130 | 81.3K | -1% | -$180.80 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2024-12-03 | D | D | 1,130 | $0.16 | 81,330 | D | — | — | (F1) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on December 3, 2024 within a one-dollar range. Actual prices ranged from $0.156 to $0.160. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |